<DOC>
	<DOC>NCT00021749</DOC>
	<brief_summary>This non-randomized study will test the safety and effectiveness of Genasense in patients with CLL.</brief_summary>
	<brief_title>Phase I/II Study of Genasense in Patients With Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description>This study is a two-part phase I-II study. Part 1 will determine the MTD of Genasense in patients with CLL. This dose will then be tested in a non-randomized, multi-center, Phase II sequential clinical trial of Genasense used alone for treatment of patients with advanced CLL. Pharmacokinetics of Genasense and kinetics of Bcl-2 down regulation and re-expression in CLL cells will be followed in selected patients.</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<criteria>Any age Must have received at least one chemotherapy regimen that included fludarabine Measurable disease At least 3 weeks since biological therapy or radiation therapy for chronic lymphocytic leukemia No previous stem cell transplantation At least 3 weeks since surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>CLL</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Chronic</keyword>
	<keyword>Cancer</keyword>
	<keyword>Adult</keyword>
	<keyword>Lymphocytic</keyword>
	<keyword>Genasense</keyword>
	<keyword>G3139</keyword>
	<keyword>Genta</keyword>
	<keyword>Bcl-2</keyword>
	<keyword>Antisense</keyword>
	<keyword>Oligonucleotide</keyword>
	<keyword>oblimerson</keyword>
</DOC>